Search research articles
Contact Us
Filters
Showing results (481-490 of 502) with videos related to
Page
of 51
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albiges, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 29, 2022
Diploid-dominant life cycles characterize the early evolution of Fungi
Kevin R Amses, D Rabern Simmons, Joyce E Longcore, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
The Journal of Experimental Medicine
|
June 13, 2024
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
Jonathan J Hodgins, John Abou-Hamad, Colin Edward O'Dwyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L Bergmann, L Albiges, M Ahrens, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation
|
March 28, 2021
Living kidney donor evaluation for all candidates with normal estimated GFR for age
François Gaillard, Lola Jacquemont, Hélène Lazareth, et al.
Therapeutic Advances in Medical Oncology
|
April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
Klaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Surgery
|
January 2, 2017
The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After
Claudio Bassi, Giovanni Marchegiani, Christos Dervenis, et al.
Page
of 51
Search research articles
Search
Showing results (481-490 of 502) with videos related to
Sort By:
Page
of 51
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albiges, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 29, 2022
Diploid-dominant life cycles characterize the early evolution of Fungi
Kevin R Amses, D Rabern Simmons, Joyce E Longcore, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
The Journal of Experimental Medicine
|
June 13, 2024
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
Jonathan J Hodgins, John Abou-Hamad, Colin Edward O'Dwyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L Bergmann, L Albiges, M Ahrens, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation
|
March 28, 2021
Living kidney donor evaluation for all candidates with normal estimated GFR for age
François Gaillard, Lola Jacquemont, Hélène Lazareth, et al.
Therapeutic Advances in Medical Oncology
|
April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
Klaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Surgery
|
January 2, 2017
The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After
Claudio Bassi, Giovanni Marchegiani, Christos Dervenis, et al.
Page
of 51